An international collaborative study has revealed detailed new information about diffuse glioma, the most common type of tumor found in some 80 percent of adult brain cancer patients, raising hopes that better understanding of these disease groups may aid improved clinical outcomes.
The study, led by researchers at The University of Texas MD Anderson Cancer Center, Columbia University Medical Center, New York, and the University...
In response to low national vaccination rates for the human papillomavirus (HPV), The University of Texas MD Anderson Cancer Center has joined...
A new procedure developed by surgeons at The University of Texas MD Anderson Cancer Center improves the accuracy of axillary staging and pathologic...
Treatment of multiple sclerosis (MS) and other inflammatory diseases may benefit by new findings from a study that identified potential therapeutic targets for a devastating disease striking some 2.3 million people worldwide.
Inflammation is an important part of body’s response against infections and tissue damage, but unresolved inflammation contributes to the pathogenesis of a variety of diseases and promotes cancer development...
The immunotherapy platform at The University of Texas MD Anderson Cancer Center and the global biopharmaceutical company AbbVie will join...
Findings from a new study reveal that PARP inhibitors, an emerging class of drugs being studied in cancer clinical trials, may be enhanced...
The University of Texas MD Anderson Cancer Center is grateful Vice President Joe Biden has inspired the creation of a national cancer moonshot...
The University of Texas MD Anderson Cancer Center today announced that it has entered into a collaborative research and development agreement...
In cancer, cell signaling pathways are the critical chain of events that can either quash or quicken disease progression.
A multi-institutional...
Kymab, a leading human monoclonal antibody biopharmaceutical company, and The University of Texas MD Anderson Oncology Research for Biologics...